Natco Pharma Limited
NSE: NATCOPHARM | Information Technology
Market Fundamentals
Stock Intelligence & News
Natco Pharma Limited
Natco Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
Read Full Analysis →Natco Pharma Limited
NATCO PHARMA LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL
Read Full Analysis →Natco Pharma Limited
Natco Pharma Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injection". |SUBJECT: Press Release
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Lupin Limited
Lupin Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection". |SUBJECT: Press Release
Read Full Analysis →Stock Picks Today: Dixon Tech, Natco Pharma, Ather Energy, NMDC And More On Brokerages' Radar
Brokerages' Radar
Read Full Analysis →Buy, Sell Or Hold: Suzlon, Wockhardt, Natco Pharma, JSW Infra, HDFC Bank, Zaggle — Ask Profit
Buy Sell Hold
Read Full Analysis →Q4 Results Outcome Live: IndiGo, NMDC, IREDA, Gujarat Gas, Patanjali Foods, Linde India, Glenmark Pharma, BEML, Natco Pharma, Titagarh Rail Systems in focus post Q4 show
Q4 Results Highlights Today Live Updates: Stay tuned to businessline for the latest live updates on Q4 earnings.
Read Full Analysis →Natco Pharma Limited
Natco Pharma Limited has submitted to the Exchange, the Audited financial results for the quarter and year ended March 31, 2026. |SUBJECT: Outcome of Board Meeting
Read Full Analysis →Natco Pharma shares crash 15% after weak Q4 results; net profit tanks 34% YoY
Natco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins and lower annual earnings weighed on investor sentiment despite a one-time tax-related benefit recorded during the quarter and full financial year.
Read Full Analysis →Natco Pharma Shares Fall 14% After Net Profit, Revenue Drops Over 39%
Shares of Natco Pharma dropped over 12% to Rs 1020.50 after the Q4FY26 results showed significant revenue and profit declines compared to the same quarter last year.
Read Full Analysis →Get instant alerts when NATCOPHARM breaks news
Join investors who track Natco Pharma Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for NATCOPHARM?
NATCOPHARM is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for Natco Pharma Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding NATCOPHARM to your custom watchlist.